In adults with diabetes who do not have advanced artery disease, a medication called evolocumab is associated with a reduction in the risk of death from any cause over five years, from 10.1% to 7.8%.
Strongly supported
Multiple high-quality studies back this claim.
Not medical advice. For informational purposes only. Always consult a healthcare professional.
In adults with diabetes who do not have advanced artery disease, a medication called evolocumab is associated with a reduction in the risk of death from any cause over five years, from 10.1% to 7.8%.
See the technical phrasing
In adults with diabetes and no significant atherosclerosis, treatment with evolocumab reduces all-cause mortality from 10.1% to 7.8% over five years, corresponding to a 24% relative risk reduction.
A drug blocks a protein that normally removes LDL receptors from the liver, so more receptors stay on the liver surface to sweep LDL cholesterol out of the blood. With less LDL in the blood, less fat builds up in artery walls, which prevents small plaques from forming and growing. This reduces the chance of blood clots that cause heart attacks and strokes, helping people live longer.
What the research says
Supports
1 study
Study: Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes
This study provides evidence supporting the claim.
Contradicts
0 studies
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies